IMS Capital Management Lowers Stake in Danaher Co. (NYSE:DHR)

IMS Capital Management lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 1.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,498 shares of the conglomerate’s stock after selling 108 shares during the quarter. Danaher comprises about 1.3% of IMS Capital Management’s holdings, making the stock its 17th biggest holding. IMS Capital Management’s holdings in Danaher were worth $2,852,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Benjamin Edwards Inc. lifted its holdings in Danaher by 1.8% during the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after buying an additional 38 shares during the last quarter. Patrick M Sweeney & Associates Inc. lifted its holdings in shares of Danaher by 3.4% during the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after purchasing an additional 40 shares during the period. Trust Co of Kansas increased its stake in Danaher by 4.1% in the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after buying an additional 40 shares during the period. Abacus Planning Group Inc. increased its stake in shares of Danaher by 0.7% during the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after acquiring an additional 40 shares during the period. Finally, Certified Advisory Corp lifted its position in Danaher by 4.5% in the second quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock valued at $231,000 after purchasing an additional 40 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 in the last three months. 11.10% of the stock is currently owned by corporate insiders.

Danaher Trading Up 0.9 %

NYSE DHR opened at $278.02 on Tuesday. The firm has a market capitalization of $205.93 billion, a PE ratio of 47.12, a price-to-earnings-growth ratio of 4.55 and a beta of 0.83. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The company has a 50-day simple moving average of $270.77 and a 200-day simple moving average of $258.06. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.05 EPS. On average, equities analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Analyst Ratings Changes

DHR has been the topic of several research analyst reports. Jefferies Financial Group assumed coverage on Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 price target on the stock. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Barclays raised their price target on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. Evercore ISI dropped their target price on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Finally, Leerink Partners upped their price target on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.